STOCK TITAN

Zomedica (ZOMDF) sales SVP adds 104K shares in indirect open-market buy

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Zomedica Corp. senior vice president of sales Russell Kevin Klass reported an open-market purchase of 104,000 shares of common stock at $0.103 per share through a spouse account, classified as indirect ownership. A separate holding entry shows he directly owns 6,001,000 common shares after the reported transactions.

Positive

  • None.

Negative

  • None.
Insider Klass Russell Kevin
Role Sr. Vice President, Sales
Bought 104,000 shs ($11K)
Type Security Shares Price Value
Purchase Common Stock, without par value 104,000 $0.103 $11K
holding Common Stock, without par value -- -- --
Holdings After Transaction: Common Stock, without par value — 104,000 shares (Indirect, spouse); Common Stock, without par value — 6,001,000 shares (Direct, null)
Footnotes (1)
Shares purchased 104,000 shares Open-market purchase, indirect via spouse
Purchase price $0.103 per share Price for 104,000 common shares
Direct holdings after transaction 6,001,000 shares Common stock, direct ownership
Indirect holdings after transaction 104,000 shares Common stock held by spouse
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirect ownership financial
""ownership_type": "indirect", "nature_of_ownership": "spouse""
Common Stock, without par value financial
""security_title": "Common Stock, without par value""
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Klass Russell Kevin

(Last)(First)(Middle)
1101 TECHNOLOGY DRIVE.
STE 100.

(Street)
ANN ARBOR. MICHIGAN 48108

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Sr. Vice President, Sales
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, without par value6,001,000D
Common Stock, without par value05/21/2026P104,000A$0.103104,000Ispouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/Kevin Klass05/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Zomedica (ZOMDF) report in this Form 4?

Zomedica reported that senior vice president of sales Russell Kevin Klass disclosed an open-market purchase of 104,000 shares of common stock. The trade was executed at a price of $0.103 per share and is reported as indirect ownership through his spouse.

Who is the insider involved in the latest Zomedica (ZOMDF) Form 4 filing?

The insider is Russell Kevin Klass, senior vice president of sales at Zomedica Corp. He reported an indirect open-market purchase of 104,000 common shares via a spouse account, along with a separate direct holding line showing a larger existing ownership position.

How many Zomedica (ZOMDF) shares were bought in the reported insider purchase?

The filing shows an open-market purchase of 104,000 Zomedica common shares. These shares are held indirectly through the insider’s spouse. The transaction is classified as a non-derivative purchase and increases the indirectly held position to 104,000 shares after the trade.

At what price were the Zomedica (ZOMDF) shares purchased in the Form 4 transaction?

The reported open-market purchase was executed at $0.103 per share. This price applies to the 104,000 Zomedica common shares acquired indirectly via the insider’s spouse, according to the transaction details in the Form 4 filing data provided.

How many Zomedica (ZOMDF) shares does the insider hold after the reported transactions?

After the reported entries, Russell Kevin Klass is shown with 6,001,000 common shares held directly. In addition, his spouse holds 104,000 common shares indirectly. These figures come from the holding and transaction lines in the Form 4 ownership table.

Is the Zomedica (ZOMDF) insider purchase a direct or indirect holding?

The 104,000-share Zomedica purchase is reported as indirect ownership. The Form 4 classifies the transaction under a spouse account, meaning the shares are held by the insider’s spouse rather than directly in his own name.